For this episode, we’re exploring the incredible benefits that can flow from connecting PhD graduates with industry. By giving researchers real-world experiences in research-intensive organisations, we can drive better commercialisation outcomes.
And it’s exactly what we’re doing as a core component of our ‘Researcher Exchange and Development within Industry’ (REDI) program - in partnership with pharmaceutical company GSK. GSK is one of the largest pharmaceutical companies in the world researching, developing and manufacturing innovative pharmaceutical medicines, vaccines and consumer healthcare products. The company has operations in Australia which employ 1,500 people in Sydney and Melbourne. GSK Australia has developed a new PhD graduate program to facilitate the cross pollination of scientific, academic research expertise with that of the Pharmaceutical Industry. The MTPConnect podcast team of Caroline Duell and Dr Rebecca Tunstall speak to GSK’s Head of Human Resources - Australia & New Zealand David Fitz-Gerald and GSK’s Director of Regulatory Affairs for Australia and New Zealand Dr Carolyn Tucek-Szabo about the launch of the new GSK PhD Graduate Innovation Program, supported by REDI over the next three years. The 12-month placement program, which builds on GSK’s successful Industry Based Learning program for undergraduate students, is open now for applications and will enable six PhD graduates to join GSK Australia assigning them to lead on core projects in areas such as early product development, medical affairs and regulatory affairs. The company is currently developing novel medicines in immuno-oncology, immuno-inflammatory, HIV, and infectious diseases (including COVID-19 therapy areas) so it’s an exciting time to throw off your lab coat to learn about industry career options. Apply by 2 December at GSK Australia’s website: https://au.gsk.com/en-au/careers/phd-graduates-and-post-doc-researchers/